Table 1. The clinicopathologic characteristics of the 209 glioma patients in the Chinese TMA cohort.
| Characteristics | All glioma (N=209) | WHO grade | |||
|---|---|---|---|---|---|
| Grade I (N=8) | Grade II (N=60) | Grade III (N=31) | Grade IV (N=110) | ||
| Gender | |||||
| Male | 144 | 5(62.5%) | 47(78.3%) | 18(58.1%) | 74(67.3%) |
| Female | 65 | 3(37.5%) | 13(21.7%) | 13(41.9%) | 36(32.7%) |
| Age at diagnosis (year) | |||||
| < 60 | 173 | 7(87.5%) | 57(95.0%) | 26(83.9%) | 83(75.5%) |
| ≥60 | 36 | 1(12.5%) | 3(5.0%) | 5(16.1%) | 27(24.5%) |
| Tumor origin | |||||
| Primary | 183 | 8(100%) | 56(93.3%) | 23(74.2%) | 96(87.3%) |
| Secondary | 26 | 0(0.0%) | 4(6.7%) | 8(25.8%) | 14(12.7%) |
| Extend of resection | |||||
| Gross total | 164 | 6(75.0%) | 49(81.7%) | 25(80.6%) | 84(76.4%) |
| Partial | 45 | 2(25.0%) | 11(18.3%) | 6(19.4%) | 26(23.6%) |
| NMI expression | |||||
| Low | 175 | 8(100.0%) | 55(91.7%) | 26(83.9%) | 86(78.2%) |
| High | 34 | 0(0.0%) | 5(8.3%) | 5(16.1%) | 24(21.8%) |
| OS (month) | |||||
| median (95% CI) | 21(17.36-24.64) | NAa | 73(56.57-89.43) | 25(15.17-34.83) | 12(10.45-13.55) |
| PFS (month) | |||||
| median (95% CI) | 19(15.36-22.64) | NAa | 73(39.84-106.16) | 25(18.25-31.75) | 10(7.66-12.34) |
Abbreviations: OS, overall survival; PFS, progression-free survival; CI, confidence interval.
a
NA, not available due to a large proportion of censored cases.